Home
  >  
Section 21
  >  
Chapter 20,638

A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model

Li, G.; Andreansky, S.; Helguera, G.; Sepassi, M.; Janikashvili, N.; Cantrell, J.; Lacasse, C.L.; Larmonier, N.; Penichet, M.L.; Katsanis, E.

Molecular Cancer Therapeutics 7(3): 721-729

2008

ISSN/ISBN: 1535-7163
PMID: 18347157
DOI: 10.1158/1535-7163.mct-07-2067
Accession: 020637339
Download citation:  
Text
  |  
BibTeX
  |  
RIS
We have documented previously that a multiple chaperone protein vaccine termed chaperone-rich cell lysate (CRCL) promotes tumor-specific T-cell responses leading to cancer regression in several mouse tumor models. We report here that CRCL vaccine generated from a mouse breast cancer (TUBO, HER2/neu positive) is also capable of eliciting humoral immunity. Administration of TUBO CRCL triggered anti-HER2/neu antibody production and delayed the progression of established tumors. This antitumor activity can be transferred through the serum isolated from TUBO CRCL-immunized animals and involved both B cells and CD4(+) T lymphocytes. Further evaluation of the mechanisms underlying TUBO CRCL-mediated humoral immunity highlighted the role of antibody-dependent cell-mediated cytotoxicity. These results suggest that tumor-derived CRCL vaccine has a wider applicability as a cancer vaccine because it can target both T-cell- and B-cell-specific responses and may represent a promising approach for the immunotherapy of cancer.

PDF emailed within 0-6 h: $19.90




Related References

Giannios, J.; Lambrinos, P.; Alexandropoulos, N. 2005: Multi-vaccine Sevina Composed of Vinorelbine Apoptotic Tumour Cell Lysate (Vatcl), Cationic Colloidal 25 mer Iss CpG Oligonucleotide (Odn)Adjuvant and Recombinant Chaperone Grp94/gp96+Her2 Differentiation Antigen Vaccine Induces Formation of Exosomes from Apcs and Humoral Cellular Immune Responses Leading to Vaccine Induced Apoptosis (Via) in Chemoresistant Distal Breast, Lung, Prostate and Ovarian Cancer Journal of Immunotherapy 28(6): 655-656
Mookerjee, A.; Graciotti, M.; Kandalaft, L.E.; Kandalaft, L. 2018: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model Bioimpacts: Bi 8(3): 211-221
Lu, J.; Zhang, Q.; Liang, C.-M.; Xia, S.-J.; Zhong, C.-P.; Wang, D.-W. 2008: Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer Asian Journal of Andrology 10(6): 883-889
Qi, Y.; Xing, K.; Zhang, L.; Zhao, F.; Yao, M.; Hu, A.; Wu, X. 2018: Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model Journal of Cancer Research and Clinical Oncology 144(10): 1945-1957
Morris, K.T.; Castillo, E.F.; Ray, A.L.; Weston, L.L.; Nofchissey, R.A.; Hanson, J.A.; Samedi, V.G.; Pinchuk, I.V.; Hudson, L.G.; Beswick, E.J. 2015: Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting protective NK cell, macrophage and T cell responses Oncotarget 6(26): 22338-22347
Bekri, S.; Rodney-Sandy, R.; Gruenstein, D.; Mei, A.; Bogen, B.; Castle, J.; Levey, D.; Cho, H.J. 2022: Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens Journal for ImmunoTherapy of Cancer 10(2)
Mukherjee, P.; Tinder, T.L.; Ginardi, A.R.; Gendler, S.J. 2001: DC-tumor cell fusion vaccine tested in preclinical mouse model of spontaneous breast cancer Proceedings of the American Association for Cancer Research Annual Meeting 42: 24
Zeng, Y.; Feng, H.; Graner, M.W.; Katsanis, E. 2003: Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity Blood 101(11): 4485-4491
Xu, J.-n.; Yang, Z.-w.; Chen, J.-p.; Chen, D.-L.; Wang, T.; Liu, M.-j.; Zhang, L.; Yang, B.-b. 2012: Protective immunity against Legionnaires' disease in an A/J mouse model using a DNA vaccine composed of an outer membrane protein (29 kDa) and the pilE fusion protein Diagnostic Microbiology and Infectious Disease 73(1): 9-15
Wang, Z.-Y.; Xing, Y.; Liu, B.; Lu, L.; Huang, X.; Ge, C.-Y.; Yao, W.-J.; Xu, M.-L.; Gao, Z.-Q.; Cao, R.-Y.; Wu, J.; Li, T.-M.; Liu, J.-J. 2012: Protective antitumor immunity induced by tumor cell lysates conjugated with diphtheria toxin and adjuvant epitope in mouse breast tumor models Chinese Journal of Cancer 31(6): 295-305
Song, N.; Guo, H.; Ren, J.; Hao, S.; Wang, X. 2018: Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model Oncology Letters 15(5): 6831-6838
Zeng, Y.; Feng, H.; Graner, M.; Katsanis, E. 2002: Dendritic cells loaded with tumor-derived multiple chaperone proteins enriched by free solution-isoelectric focusing induce significant protective immunity Proceedings of the American Association for Cancer Research Annual Meeting 43: 977
Gebert, J.; Gelincik, O.; Oezcan-Wahlbrink, M.; Marshall, J.D.; Hernandez-Sanchez, A.; Urban, K.; Long, M.; Cortes, E.; Tosti, E.; Katzenmaier, E.-M.; Song, Y.; Elsaadi, A.; Deng, N.; Vilar, E.; Fuchs, V.; Nelius, N.; Yuan, Y.P.; Ahadova, A.; Sei, S.; Shoemaker, R.H.; Umar, A.; Wei, L.; Liu, S.; Bork, P.; Edelmann, W.; von Knebel Doeberitz, M.; Lipkin, S.M.; Kloor, M. 2021: Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity with Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model Gastroenterology 161(4): 1288-1302.E13
You, J.; Wang, C.-l.; Hao, X.-s. 2007: Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity Zhonghua Yi Xue Za Zhi 87(39): 2785-2790
Highton, A.J.; Kojarunchitt, T.; Girardin, A.; Hook, S.; Kemp, R.A. 2015: Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma Immunology and Cell Biology 93(7): 634-640
Kao, J.Y.; Zhang, M.; Chen, C.-M.; Chen, J.-J. 2005: Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer Immunology Letters 101(2): 154-159
Hauser, C.; Zarei, S.; Arrighi, I. 2003: Transfection of dendritic cells with antigen-encoding RNA generates a cellular vaccine that induces protective CD8 T cell-dependent antiviral immunity Journal of Investigative Dermatology 121(1): 0858
Sypniewska, R.K.; Hoflack, L.; Tarango, M.; Gauntt, S.; Leal, B.Z.; Reddick, R.L.; Gravekamp, C. 2005: Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy Breast Cancer Research and Treatment 91(1): 19-28
Hardin, M.O.; Vreeland, T.J.; Clifton, G.T.; Hale, D.F.; Herbert, G.S.; Greene, J.M.; Jackson, D.O.; Berry, J.E.; Nichols, P.; Yin, S.; Yu, X.; Wagner, T.E.; Peoples, G.E. 2018: Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine ImmunoTherapy 10(5): 373-382
Kalli, K.R.; Block, M.S.; Kasi, P.M.; Erskine, C.L.; Hobday, T.J.; Dietz, A.; Padley, D.; Gustafson, M.P.; Shreeder, B.; Puglisi-Knutson, D.; Visscher, D.W.; Mangskau, T.K.; Wilson, G.; Knutson, K.L. 2018: Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 24(13): 3014-3025